BSF-funded research advances melanoma prognosis: identifying high-risk patients early

Melanoma is the deadliest form of skin cancer with increasing worldwide incidence. If the tumour is found early, survival rates are favourable. However, a small number of stage 1 and 2 melanomas may progress and, as such, in the absence of any personalised risk stratification, all patients are managed as if they are at risk of recurrence.

Previously, BSF-funded researchers identified two proteins, AMBRA1 and loricrin, in the outer layer of the skin, whose presence is associated with low risk of disease progression.